Qiagen has launched the EZ2 Connect MDx IVD platform for automated sampling in diagnostic laboratories.

The company is offering the platform for widescale use 18 months after it was made available for research.

The EZ2 Connect MDx device has a high degree of automation and enables laboratories to perform parallel purification of DNA and RNA from up to 24 samples in 30 minutes.

Available in Canada, the US and other countries, the platform has EU CE-IVD compliance marking for in-vitro devices (IVD) for the European Union and other countries accepting this designation.

Qiagen Molecular Diagnostics Business Area head and senior vice-president Jean-Pascal Viola said: “EZ2 Connect MDx puts standardised and efficient nucleic acid purification in reach of any clinical lab.

“It solves the challenges of many clinical diagnostics labs that have to provide diagnostics results quickly, that have to deal with fluctuating sample numbers as well as a large variety of sample types and quality.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EZ2 Connect MDx uses magnetic-bead technology to extract nucleic acids from serum, blood plasma, stool and other sample types.

It features prefilled and sealed reagent cartridges for process safety along with integrated cameras for load checking.

Other features of the device include on-board pipetting and heating, UV decontamination, and automated piercing of the sealed cartridge.

Designed to handle a range of sample materials, EZ2 Connect MDx complements the company’s offering of automated IVD nucleic extraction platforms, which includes QIAsymphony and QIAcube Connect MDx.

EZ2 Connect MDx can be used with research kits (MBA) in research mode or with EZ1 DSP kits in dedicated IVD mode along with protocols for diagnostic workflows.

It can also use the QIAsphere digital laboratory ecosystem for complete integration into the digital infrastructure of a lab, enabling remote instrument management.

Additionally, the platform combines process safety, ease of use and the EZ1’s robustness with improved throughput and digital features.

Last September, Qiagen and Neuron23 signed an agreement to develop a next-generation sequencing (NGS) companion diagnostic (CDx) for the latter’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor to treat Parkinson’s disease.